Business Context and Reporting Period
Company: Smith & Nephew plc (LSE: SN, NYSE: SNN)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: September 8, 2026
Business Overview: A global medical technology company focused on orthopaedics, sports medicine, ENT, and advanced wound management. The company reported annual sales of $6.2 billion for the fiscal year 2025.
Key Financial Metrics and Debt Structure
This filing focuses on capital structure management rather than operational financial results. Key debt metrics include:
- Target Security: 2.032% Senior Notes due 2030.
- Aggregate Principal Outstanding: $900,000,000.
- Tender Offer Cap: Up to $250,000,000 (Maximum Tender Amount).
- Reference Security: 4.375% U.S. Treasury due August 31, 2031.
- Fixed Spread: 55 basis points.
Note: The filing does not provide current revenue, profit, cash flow, or liquidity figures for the period ending September 2026.
Material Changes and Strategic Actions
The company announced a cash tender offer to purchase up to $250 million of its 2030 notes. This action is part of a strategy to proactively manage the debt portfolio and extend the average maturity profile of existing debt. Concurrently, the company intends to issue new senior notes due 2036 (the "New Notes").
- Financing Condition: The tender offer is conditioned on the company receiving sufficient gross proceeds from the concurrent offering of New Notes to fund the repurchase of tendered notes.
- Allocation Preference: The company intends to give some degree of preference in the allocation of New Notes to investors who validly tender their existing 2030 notes.
Indicative Timetable
| Event | Date/Time |
|---|---|
| Launch Date | September 8, 2026 |
| Price Determination Date | September 15, 2026 (4:00 p.m. NYC time) |
| Expiration Time | September 15, 2026 (5:00 p.m. NYC time) |
| Results Announcement | September 16, 2026 (Expected) |
| Settlement Date | September 18, 2026 (Expected) |
Guidance, Risks, and Contingencies
Management Commentary: The primary objective is to extend the debt maturity profile. The company reserves the right to increase or decrease the Maximum Tender Amount by press release no later than the third business day before the Expiration Time.
Risks and Contingencies:
- Proration: If the tendered amount exceeds $250 million, acceptance will be prorated.
- Financing Failure: The offer is subject to the Financing Condition; if the concurrent New Notes offering does not raise sufficient funds, the tender offer may not proceed.
- Forward-Looking Risks: The filing lists standard risks including geopolitical conflicts (Europe/Middle East), economic conditions affecting healthcare payers, regulatory approvals, supply chain disruptions, cybersecurity, and foreign exchange volatility.
Investor Verification Checklist
- Verify the final "Maximum Tender Amount" as the company reserves the right to adjust it prior to the third business day before expiration.
- Confirm the satisfaction of the "Financing Condition" (successful issuance of 2036 New Notes) before assuming the tender offer will close.
- Review the "Offer to Purchase" for specific pricing calculations based on the Price Determination Date (September 15, 2026).
- Check for proration notices if the tender is oversubscribed.
- Consult the most recent Form 20-F (year ended Dec 31, 2025) and interim Form 6-K (six months ended June 27, 2026) for operational financial data not included in this filing.